Clinical response and failure to alter lymphatic function in a guinea pig model: DISCUSSION (Part 2)

In: Octreotide

7 Aug 2012

Ballinger and Farthing described the successful use of octreotide in a patient with primary intestinal lymphangiectasia and showed that octreotide decreased enteric protein loss, and led to resolution of pleural effusions and improvement in serum albumin levels. Kuroiwa et al , Strehl et al and Klingenberg et al reported individual patients with primary intestinal lymphangiectasia who also were successfully treated with octreotide; remarkably, one study noted resolution of both endoscopic and histological changes. Recently, Lee et al reported that octreotide improved protein-losing enteropathy due to secondary lymphangiectasia thought to be induced by hepatitis B-associated liver cirrhosis.

Thus, the current literature reports that octreotide has improved the clinical and laboratory features of intestinal lymphangiectasia in six different patients: four with primary intestinal lymphangiectasia and two with secondary intestinal lymphangiectasia. We could not identify any cases in which a patient with intestinal lymphangiectasia failed to respond to octreotide. Anecdotally, we and some of our other colleagues have found that not all patients respond to octreotide. Thus, we feel this 100% success rate likely represents a publication bias towards ‘positive studies’. Best quality drugs are waiting – order antibiotics online to spend less time and money.

About this blog

Blog invites submissions of review articles, reports on clinical techniques, case reports, conference summaries, and articles of opinion pertinent to the control of pain and anxiety in dentistry.